B BRAUN

Manufacturer's Declaration

in relation to Regulation (EU) 2023/607 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices, in particular with respect to

- the validity of certificates issued under Council Directive 90/385/EEC on Active Implantable Medical Devices (AIMDD) or Council Directive 93/42/EEC on Medical Devices (MDD) (Directive Certificates) *and/or*[1]
- the compliance of the devices and us as their manufacturer with the conditions for the continued placing on the market and putting into service

Manufacturer name	B. Braun Medical AG
Manufacturer address and contact details	Seesatz 17, 6204 Sempach, Switzerland
Single Registration Number (SRN) (if available)	CH-MF-000017781

Authorised Representative name (if applicable)	B. Braun Melsungen AG
Authorised Representative address and contact details	Carl-Braun-Straße , 1 34212 Melsungen
Single Registration Number (SRN) (if available)	DE-AR-000000202

Notified body name (if applicable)	DEKRA Certification B.V. □ See attached schedule
Notified body number (if applicable)	0344 □ See attached schedule
Directive Certificate number(s) to which this confirmation is made (if applicable)	2113812DE03 2113812DE05 2113812CE02 2113812CE01 □ See attached schedule
Original expiry date as indicated on the Directive Certificate prior to the extension of the validity (if applicable)	26.05.2024 □ See attached schedule
End date of extended validity/transition period	31.12.2027 □ See attached schedule

[1] The first condition is not applicable in case of devices for which the conformity assessment procedure pursuant to MDD did not require the involvement of a notified body, for which the declaration of conformity was drawn up prior to 26 May 2021 and for which the conformity assessment procedure pursuant to this Regulation requires the involvement of a notified body.

Effective

We, as the manufacturer declare under our sole responsibility:

- for the above listed **Directive Certificate** (or see attached schedule, if multiple certificates) the conditions for the legal extension of validity as required in Article 120.2 of the MDR are met *and/or*[2]
- the listed **device(s)** in the attached schedule and we as their manufacturer are in compliance with the conditions listed in Article 120.3c of the MDR for continued placing on the market and putting into service,

namely by fulfilling the following conditions:

➢ **Directive Certificate(s)** as listed above or in the attached schedule

- Directive Certificate(s) covering the listed device(s) was/were issued after 25 May 2017, was/were valid on 26 May 2021 and have not been withdrawn afterwards.

  Choose applicable statements:

  ☐ Expired *before* 20 March 2023:
  - ☐ Before the original date of expiry as indicated on the Directive Certificate(s), we and the notified body have signed written agreement(s) in accordance with Section 4.3, second subparagraph of Annex VII to this Regulation for the conformity assessment(s) in respect of the device(s) covered by the expired certificate(s) or in respect of a device(s) intended to substitute that/those device(s), or
  - ☐ A Competent Authority has granted a derogation from the applicable conformity assessment procedure in accordance with Article 59(1) MDR (may be provided upon request), or
  - ☐ A Competent Authority has required the manufacturer, in accordance with Article 97(1) MDR, to carry out the applicable conformity assessment procedure (may be provided upon request)

  Choose one of the following statements only if a derogation per Article 59(1) or a requirement per Article 97(1) has been granted by a Competent Authority:

  - ☐ Formal application(s) to the notified body in accordance with Section 4.3, first subparagraph of Annex VII MDR for conformity assessment has/have been made or will be made/submitted by us to a notified body no later than 26 May 2024 for the device(s) listed in the attached schedule or its/their substitute(s) and signed written agreement(s) is/will be in place in accordance with Section 4.3, second subparagraph of Annex VII MDR before 26 September 2024.
  - ☐ We do not intent to lodge an application for conformity assessment by 26 May 2024, therefore the transition period will end on 26 May 2024.

  ☑ Expired/expires *after* 20 March 2023:

  Choose one applicable statement:

  - ☑ Formal application(s) to the notified body in accordance with Section 4.3, first subparagraph of Annex VII MDR for conformity assessment has/have been made or will be made/submitted by us to a notified body no later than 26 May 2024 for the device(s) listed in the attached schedule or its/their substitute(s) and signed written agreement(s) is/will

[2] The first condition is not applicable in case of devices for which the conformity assessment procedure pursuant to MDD did not require the involvement of a notified body, for which the declaration of conformity was drawn up prior to 26 May 2021 and for which the conformity assessment procedure pursuant to this Regulation requires the involvement of a notified body

B BRAUN

be in place in accordance with Section 4.3, second subparagraph of Annex VII MDR before 26 September 2024.
The application has been made on 22.06.2020
The certification agreement has been signed on 29.06.2020
The update transition period agreement has been signed on 03.01.2024

☐ We do not intent to lodge an application for conformity assessment by 26 May 2024, therefore the transition period will end on 26 May 2024.

➢ **Upclassified devices**

In case of devices for which the conformity assessment procedure pursuant to MDD did not require the involvement of a notified body, for which the declaration of conformity was drawn up prior to 26 May 2021 and for which the conformity assessment procedure pursuant to this Regulation requires the involvement of a notified body:

Choose one applicable statement:

☐ Formal application(s) to the notified body in accordance with Section 4.3, first subparagraph of Annex VII MDR for conformity assessment has/have been made or will be made/submitted by us to a notified body no later than 26 May 2024 for the device(s) listed in the attached schedule or its/their substitutes and signed written agreement(s) is/will be in place in accordance with Section 4.3, second subparagraph of Annex VII MDR before 26 September 2024.
☐ We do not intent to lodge an application for conformity assessment by 26 May 2024, therefore the transition period will end on 26 May 2024.

➢ **Quality Management System (QMS)**

Choose one applicable statement:

☐ A QMS in accordance with Article 10(9) MDR will be put in place by no later than 26 May 2024.
☑ A QMS in accordance with Article 10(9) MDR is in place.
☐ A notified body has issued the attached certificate for the MDR-compliant QMS.

➢ **Device(s) as listed in the attached schedule**

- The device(s) continue to comply with the AIMDD or MDD.
- There are no significant changes in the design and intended purpose.
- The device(s) do not present an unacceptable risk to health or safety of patients, users or other persons, or to other aspects of the protection of public health.

Signed for and on behalf of the manufacturer:

Dr. Michael Gluschke
Director Global Regulatory Affairs
B. Braun Medical AG
CoE Infection Prevention & Renal Fluids
Phone: +41 58 258 51 48
michael.gluschke@bbraun.com

Peter Egli
Head of Quality Management
B. Braun Medical AG
CoE Infection Prevention & Renal Fluids
Phone: +41 58 258 51 84
peter.egli@bbraun.com

Effective

AV4008

Effective

Schedule of Devices
The above Manufacturer's Declaration is valid for the following devices:

Identification of the device(s)[3] (e.g., device name, family/group name device model or catalogue number)	**Directive Certificate number(s) to which this confirmation is made** (if applicable)	**Basic UDI**	**Original expiry date as indicated on the Directive Certificate (s) prior to the extension of the validity** (if applicable)	**Notified Body name and number that issued the Directive Certificate** (if applicable)	**Notified Body name and number where the MDR application was lodged/contract signed** (if applicable)	**End date of extended validity / transition period**	**Substitute Device(s)** (if applicable)
Lavasurge	2113812CE01	40392390000009082U	26.05.2024	DEKRA Certification B.V. 0344	DEKRA Certification B.V. 0344	31.12.2027	N/A
Prontoderm Solution	2113812DE03 2113812CE02	40392390000009182X	26.05.2024	DEKRA Certification B.V. 0344	DEKRA Certification B.V. 0344	31.12.2027	N/A
Prontoderm Foam	2113812DE03 2113812CE02	40392390000009152R	26.05.2024	DEKRA Certification B.V. 0344	DEKRA Certification B.V. 0344	31.12.2027	N/A
Prontoderm Wipes	2113812DE03 2113812CE02	40392390000009192Z	26.05.2024	DEKRA Certification B.V. 0344	DEKRA Certification B.V. 0344	31.12.2027	N/A

[3] for devices with AIMDD/MDD certificate(s) the identification should be as in the certificate, and only if the certificate has a generic scope it should be as defined above)

Effective

AV4008

Effective

ProntOral	2113812DE03 2113812CE02	40392390000009202J	26.05.2024	DEKRA Certification B.V. 0344	DEKRA Certification B.V. 0344	31.12.2027	N/A
Prontoderm Nasal Gel	2113812DE03 2113812CE02	40392390000009162T	26.05.2024	DEKRA Certification B.V. 0344	DEKRA Certification B.V. 0344	31.12.2027	N/A
Prontosan acute Wound Gel	2113812DE05 2113812CE01	40392390000009212L	26.05.2024	DEKRA Certification B.V. 0344	DEKRA Certification B.V. 0344	31.12.2027	N/A
Prontosan Wound Spray*	2113812CE01*	40392390000009252U	26.05.2024	DEKRA Certification B.V. 0344	DEKRA Certification B.V. 0344	31.12.2027	N/A

*For Prontosan Wound Spray a separate Manufacturers declaration is available for the Design Examination certificate 2113812DE06 (original expiry date before 20.03.2023)

Effective